Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J S Weber

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1992
The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphomaJ S Weber, J C Yang, S L Topalian, et al.
Cancer Immunology, Immunotherapy : CII|May 11, 1999
A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neuV Pullarkat, Y Deo, J Link, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 19, 2010
Assessing oncologic benefit in clinical trials of immunotherapy agentsR K Hales, J Banchereau, A Ribas, et al.
Journal of Biological Response Modifiers|October 1, 1990
In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytesB A Fox, P J Spiess, A Kasid, et al.
Pharmacopsychiatry|October 9, 2014
Antipsychotic agents used to augment clozapine during long-term inpatient hospitalizationsJ G Leung, K N R Chengappa, E Ivanov, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 15, 1991
Phenotypic characterization of murine tumor-infiltrating T lymphocytesR M Karpati, S M Banks, B Malissen, et al.
Human Gene Therapy|August 20, 1996
RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulationsJ J Mulé, M Custer, B Averbook, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2013
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trialsJ D Wolchok, J S Weber, M Maio, et al.
Cellular Immunology|April 15, 1999
Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cellsJ S Kuniyoshi, C J Kuniyoshi, A M Lim, et al.
Journal for Immunotherapy of Cancer|February 8, 2019
HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristicsAndressa S Laino, B C Betts, A Veerapathran, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1992
The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphomaJ S Weber, J C Yang, S L Topalian, et al.
Cancer Immunology, Immunotherapy : CII|May 11, 1999
A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neuV Pullarkat, Y Deo, J Link, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 19, 2010
Assessing oncologic benefit in clinical trials of immunotherapy agentsR K Hales, J Banchereau, A Ribas, et al.
Journal of Biological Response Modifiers|October 1, 1990
In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytesB A Fox, P J Spiess, A Kasid, et al.
Pharmacopsychiatry|October 9, 2014
Antipsychotic agents used to augment clozapine during long-term inpatient hospitalizationsJ G Leung, K N R Chengappa, E Ivanov, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 15, 1991
Phenotypic characterization of murine tumor-infiltrating T lymphocytesR M Karpati, S M Banks, B Malissen, et al.
Human Gene Therapy|August 20, 1996
RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulationsJ J Mulé, M Custer, B Averbook, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2013
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trialsJ D Wolchok, J S Weber, M Maio, et al.
Cellular Immunology|April 15, 1999
Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cellsJ S Kuniyoshi, C J Kuniyoshi, A M Lim, et al.
Journal for Immunotherapy of Cancer|February 8, 2019
HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristicsAndressa S Laino, B C Betts, A Veerapathran, et al.
Pageof 5